Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Dravet syndrome
Pharma
Eisai ends lorcaserin development in Dravet syndrome
In the wake of a market pull in obesity nearly five years ago, the other shoe has dropped for Eisai’s serotonin 2C receptor agonist lorcaserin.
Fraiser Kansteiner
Nov 18, 2024 10:18am
UCB bangs drum for epilepsy drug in ‘sound of profound’ videos
Jun 19, 2024 7:00am
NICE signs off on reimbursement for Jazz's cannabinoid med
Feb 1, 2023 11:52am
2 players vied before UCB emerged to buy Zogenix for $1.9B
Feb 1, 2022 5:24pm
Zogenix's Fintepla ready to challenge GW Pharma in rare epilepsy
Jun 26, 2020 11:15am
GW Pharma wins historic FDA nod for cannabis-based drug
Jun 25, 2018 5:25pm
